Arrowhead Pharmaceuticals has been granted breakthrough therapy designation from the US Food and Drug Administration (FDA) regarding its potential RNA interference (RNAi) therapeutic, plozasiran. The treatment is said to have shown “promising results” in trials...

Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), has announced a collaboration with 3P innovation, a leading engineering company and supplier of automated...